These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27679977)

  • 21. The 25th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Miyahira AK; Soule HR
    Prostate; 2019 Sep; 79(12):1471-1486. PubMed ID: 31334865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
    Miyahira AK; Soule HR
    Prostate; 2022 Oct; 82(14):1346-1377. PubMed ID: 35852016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.
    Nienhuis HH; Gaykema SB; Timmer-Bosscha H; Jalving M; Brouwers AH; Lub-de Hooge MN; van der Vegt B; Overmoyer B; de Vries EG; Schröder CP
    Pharmacol Ther; 2015 Mar; 147():63-79. PubMed ID: 25444756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer immunotherapy: beyond immunity to curability.
    Simons JW
    Cancer Immunol Res; 2014 Nov; 2(11):1034-43. PubMed ID: 25367978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer.
    Naitoh J; Witte O; Belldegrun A
    Cancer Res; 1998 Jul; 58(13):2895-900. PubMed ID: 9661908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 21st Annual Prostate Cancer Foundation Scientific Retreat report.
    Miyahira AK; Simons JW; Soule HR
    Prostate; 2015 Aug; 75(11):1119-28. PubMed ID: 25893521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
    Bryant G; Wang L; Mulholland DJ
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report.
    Rhodes KE; Simons JW; Soule HR
    Prostate; 2010 Jun; 70(8):916-20. PubMed ID: 20166134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic targeting of prostate cancer.
    Cress AE; Mohla S
    Cancer Biol Ther; 2004 Oct; 3(10):1028-30. PubMed ID: 15539935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conference scene: Immune signatures in the tumor and beyond.
    Kandalaft LE; Kalos M; Melief CJ; Speiser DE; Coukos G
    Immunotherapy; 2012 Aug; 4(8):761-72. PubMed ID: 22947003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 19th annual Prostate Cancer Foundation scientific retreat.
    Walia G; Pienta KJ; Simons JW; Soule HR
    Cancer Res; 2013 Aug; 73(16):4988-91. PubMed ID: 23536559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Immunotherapy to the Tumor Microenvironment.
    Dougan M; Dougan SK
    J Cell Biochem; 2017 Oct; 118(10):3049-3054. PubMed ID: 28332219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
    Olson B; Patnaik A
    Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer.
    Stuchbery R; Kurganovs NJ; McCoy PJ; Nelson CC; Hayes VM; Corcoran NM; Hovens CM
    Curr Cancer Drug Targets; 2015; 15(5):394-405. PubMed ID: 25882061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 30th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Miyahira AK; Soule HR
    Prostate; 2024 Oct; 84(14):1271-1289. PubMed ID: 39021296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
    Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
    Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer relevant antigens and enzymes for targeted drug delivery.
    Barve A; Jin W; Cheng K
    J Control Release; 2014 Aug; 187():118-32. PubMed ID: 24878184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.